Your browser doesn't support javascript.
loading
Care partner-informed meaningful change thresholds for the Clinical Dementia Rating-Sum of Boxes for trials of early Alzheimer's disease.
Lansdall, Claire J; Teng, Edmond; Chague, Jerome; Palanganda, Rohan; Delmar, Paul; Smith, Janice; Cummings, Jeffrey L; McDougall, Fiona.
Afiliação
  • Lansdall CJ; Product Development, Patient-Centered Outcomes Research, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Teng E; Early Clinical Development, Genentech, Inc., South San Francisco, California, USA.
  • Chague J; Product Development, Data Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Palanganda R; Product Development, Data Science, Roche Products Ltd, Welwyn Garden City, UK.
  • Delmar P; Product Development, Data Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Smith J; Product Development, Neuroscience, Roche Products Ltd, Welwyn Garden City, UK.
  • Cummings JL; Chambers-Grundy Center for Transformative Neuroscience, University of Nevada, Las Vegas, Nevada, USA.
  • McDougall F; Product Development, Patient-Centered Outcomes Research, Genentech, Inc., South San Francisco, California, USA.
Alzheimers Dement ; 20(9): 5889-5900, 2024 Sep.
Article em En | MEDLINE | ID: mdl-39015065
ABSTRACT

INTRODUCTION:

Consensus definitions of meaningful within-patient change (MWPC) on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) are needed. Existing estimates use clinician-rated anchors in clinically diagnosed Alzheimer's disease (AD) populations. Incorporating the care partner perspective offers important insights, and evaluating biomarker-confirmed cohorts aligns estimates with ongoing trials.

METHODS:

Anchor-based analyses were conducted to evaluate MWPC on the CDR-SB in early AD (Tauriel; NCT03289143) using Caregiver Global Impression of Change in memory or daily activities.

RESULTS:

Across time points and anchors, mean CDR-SB changes associated with the "somewhat worse" category ranged from 1.50 to 2.12 in early AD, 1.07 to 2.06 in mild cognitive impairment-AD, and 1.79 to 2.25 in mild AD.

DISCUSSION:

The proposed ranges are appropriate to define meaningful progression on the CDR-SB in similar cohorts and support the interpretation of treatment benefit through MWPC analyses. Thresholds should be calibrated to the context of use; lower/higher thresholds may be applicable in studies of earlier/later disease over shorter/longer durations. HIGHLIGHTS Within-patient CDR-SB change thresholds are provided using caregiver-rated anchors. 1.5 to 2.5 points may be an appropriate range in early AD trials of similar durations. Cumulative distribution function plots illustrate the benefit of a given treatment. When selecting thresholds, the target population and study design should be considered.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cuidadores / Progressão da Doença / Doença de Alzheimer Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Alzheimers Dement Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cuidadores / Progressão da Doença / Doença de Alzheimer Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Alzheimers Dement Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suíça